Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) announces it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) (“Evotec”) for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.
Read the full article: Halozyme Withdraws Proposal to Acquire Evotec //
Source: https://www.prnewswire.com/news-releases/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discussions-302314226.html